Clinical Trial Update: Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis [Phase 1]

View source ↗

Summary

Phase 1 trial of iododoxorubicin in patients with primary systemic amyloidosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• Iododoxorubicin (iododoxorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Primary Systemic Amyloidosis | Phase 1 | Status: TERMINATED